Medicare Lab Tests: Big Payment Cuts Ahead?

The Centers for Medicare & Medicaid Services (CMS) have issued preliminary 2027 payment rates for clinical laboratory services, which could alter how common tests are reimbursed for Medicare beneficiaries. The proposed rates, based on recent private insurer payment data, suggest Medicare has been overpaying by approximately 16 percent compared to private payers, potentially saving $1 billion annually.

These changes are expected to lead to the largest reductions in genomic sequencing, molecular pathology, and immunology testing. While routine chemistry tests may see an average reduction of 16 percent, the impact on patient out-of-pocket costs is not expected to be direct. However, industry groups like Quest Diagnostics argue the current reporting system has flaws and advocate for legislative reform.

Lab industry representatives warn that substantial reimbursement cuts could compromise patient access to testing, especially in rural or underserved regions. CMS states that any significant payment reductions will be phased in annually, capped at 15 percent through 2029, to mitigate drastic impacts.

CMS is currently accepting public comments on these preliminary rates for 30 days. Final payment rates are anticipated to be published in November. Concerns remain about potential long-term effects on laboratory viability and patient access if reimbursement continues to decline.